Guggenheim Capital LLC lifted its holdings in shares of STERIS plc (NYSE:STE - Free Report) by 67.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 3,440 shares of the medical equipment provider's stock after acquiring an additional 1,383 shares during the quarter. Guggenheim Capital LLC's holdings in STERIS were worth $707,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of STE. Franklin Resources Inc. lifted its position in shares of STERIS by 171.2% during the third quarter. Franklin Resources Inc. now owns 838,569 shares of the medical equipment provider's stock worth $191,370,000 after purchasing an additional 529,308 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of STERIS by 30.8% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,970 shares of the medical equipment provider's stock worth $2,275,000 after acquiring an additional 2,583 shares in the last quarter. Wilmington Savings Fund Society FSB bought a new stake in shares of STERIS in the 3rd quarter valued at approximately $9,949,000. Merit Financial Group LLC acquired a new stake in shares of STERIS during the 4th quarter valued at approximately $260,000. Finally, Blue Trust Inc. lifted its stake in STERIS by 19.9% during the fourth quarter. Blue Trust Inc. now owns 1,128 shares of the medical equipment provider's stock worth $232,000 after purchasing an additional 187 shares during the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have weighed in on STE shares. JMP Securities reissued a "market outperform" rating and set a $265.00 target price on shares of STERIS in a report on Thursday, April 10th. Needham & Company LLC reissued a "hold" rating on shares of STERIS in a report on Monday, April 7th. Stephens reaffirmed an "overweight" rating and set a $240.00 target price on shares of STERIS in a report on Thursday, February 6th. Finally, Piper Sandler raised their price target on STERIS from $260.00 to $265.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $258.75.
View Our Latest Stock Report on STERIS
STERIS Price Performance
STE stock traded up $0.26 during trading on Monday, hitting $225.26. The company had a trading volume of 610,377 shares, compared to its average volume of 526,408. The firm has a market capitalization of $22.13 billion, a price-to-earnings ratio of 47.83 and a beta of 0.87. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. The business has a 50 day moving average of $222.89 and a 200 day moving average of $218.85. STERIS plc has a fifty-two week low of $200.98 and a fifty-two week high of $248.24.
STERIS (NYSE:STE - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. As a group, research analysts predict that STERIS plc will post 9.08 earnings per share for the current year.
STERIS Dividend Announcement
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 21st. Stockholders of record on Thursday, February 20th were issued a $0.57 dividend. The ex-dividend date was Thursday, February 20th. This represents a $2.28 annualized dividend and a dividend yield of 1.01%. STERIS's dividend payout ratio (DPR) is 48.41%.
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Featured Articles
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
